Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial
Atrial fibrillation (AF) is the most common arrhythmia and has an increasing impact on public health because of its morbidity and mortality. Clinical and diagnostic tests to predict the recurrence of arrhythmia and clinical events before AF becomes permanent are still an open issue.
307 out of 1442 patients in sinus rhythm, at high risk of recurrence of AF enrolled in the GISSI-AF study, participated in a substudy with echocardiographic and biohumoral evaluation at baseline and at 12-month follow-up. The relations between biomarker concentrations and echocardiographic parameters with study endpoints in 1 year, were analysed by a stepwise multivariable Cox model (entry criteria p < 0.5 and stay criteria p < 0.2).
The echocardiographic variables, cardiac markers and clinical variables considered in the statistical model indicated a higher concentration of NT-proBNP at baseline as the strongest factor related to time of first AF recurrence (HR 1.42; 95 %CI 1.23–1.46), first CV hospitalization (HR 1.58; 95 %CI 1.31–1.92) and increasing duration of recurrent AF (OR 2.16; 95 %CI 1.52–3.08). Valsartan treatment was not related to clinical events.
In patients in sinus rhythm with a history of AF a higher concentration of NT-proBNP at baseline was the strongest independent risk factor for first AF recurrence and its duration, and for the first hospital admission for cardiovascular reasons.
KeywordsAtrial fibrillation Echocardiography Circulating biomarkers Natriuretic peptides Atrial fibrillation recurrence Hospitalizations Clinical trial
We thank the patients, nurses and cardiologists who participated in the echocardiographic and biohumoral substudy of GISSI-AF. We are grateful to J.D. Baggott for language editing.
Compliance with Ethical standards
The GISSI Studies and this substudy are supported by Associazione Nazionale Medici Cardiologi Ospedalieri and by IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”. Funding was provided by Novartis, which had no role in the design or conduction of the trial, the collection, analysis, or interpretation of the data; or the writing of the report. Reagents for measuring circulating biomarkers were kindly provided by B.R.A.H.M.S. AG and Roche Diagnostics GmbH.
Conflict of interests and disclosures
Drs. Masson, Staszewsky, Maggioni, Disertori and Latini received institutional research support from Novartis Pharma, the company that funded the GISSI-AF trial.
- 2.Camm AJ, Lip GY, De Caterina R, et al. ESC committee for practice guidelines-CPG; document reviewers. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation--developed with the special contribution of the european heart rhythm association. Europace. 2012;14:1385–413.CrossRefPubMedGoogle Scholar
- 3.January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/american heart association task force on practice guidelines and the heart rhythm society. J Am Coll Cardiol. 2014;64:e1–76.Google Scholar
- 5.Hijazi Z, Wallentin L, Siegbahn A, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (apixaban for the prevention of stroke in subjects with atrial fibrillation). J Am Coll Cardiol. 2013;61:2274–84.CrossRefPubMedGoogle Scholar
- 6.Hijazi Z, Siegbahn A, Andersson U, et al. ARISTOTLE investigators. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2014;129:625–34.CrossRefPubMedGoogle Scholar
- 10.Disertori M, Latini R, Maggioni AP, et al. GISSI-AF investigators. Rationale and design of the GISSI-atrial fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med (Hagerstown). 2006;7:29–38.CrossRefGoogle Scholar
- 11.Lang RM, Bierig M, Devereux RB, et al. Chamber quantification writing group; american society of Echocardiography’s guidelines and standards committee; european association of echocardiography. Recommendations for chamber quantification: a report from the american society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the european society of cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.CrossRefPubMedGoogle Scholar
- 13.Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C, et al. Latini R; GISSI-AF investigators. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart. 2010;96:1909–14.CrossRefPubMedGoogle Scholar
- 18.Schnabel RB, Wild PS, Wilde S, et al. Multiple biomarkers and atrial fibrillation in the general population. PLoS One. 2014;17:9e112486.Google Scholar